Arkady Nekrasov
Petrovax Pharm founder and Chairman of the Board
  • Petrovax Pharm is founded
  • Polyoxidonium® and Grippol® are registered
  • Prof. Arkady Nekrasov and his team are awarded the Russian Federation State Prize for Polyoxidonium® and Grippol® development and implementation in the country’s healthcare system.
  • A facility is launched to manufacture APIs, semi-solid and solid dosage forms (tablets) and injectables.
  • Partnership with Solvay Pharma (currently, Abbott).
  • Longidaze® is launched to the market.
  • A state-of-the-art GMP-compliant manufacturing and warehousing complex is put in operation in Pokrov (Podolsk District, Moscow Region).
  • Launch of a unique pre-filled syringe line.
  • Grippol® Pluspreservative-free innovative influenza vaccine is launched to the market.
  • Development and manufacturing of the A/H1N1 pandemic influenza vaccines MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
  • The WHO approves Azoximer bromide as the INN for Polyoxidonium®.
  • Grippol® plus vaccine manufacturing for the National Immunization Schedule.
  • Partnership with Pfizer to localize production of a 13-valent pneumococcal conjugate vaccine (including vaccine manufacturing and registration). This project received a Russian Platinum Ounce award.
  • Polyoxidonium®Vet Solution is registered for veterinary use.
  • EU GMP audit successful completion.
  • NPO Petrovax Pharm controlling interest is acquired by Interros Group owner and founder Vladimir Potanin’s company.
  • Agreements are signed on Grippol Plus flu vaccine manufacturinglocalization in the Republic of Belarus and Iran.
  • Imoferaza®, an innovative special care cosmetic cream for post-trauma, post-surgical and post-acne scars is launched to the market.
  • The WHO approves bovhyaluronidase azoximer as the INN for Longidaze®.
  • The Russian Ministry of Health licenses Petrovax Pharm to manufacture Grippol® Plus, a Russian influenza vaccine, using flu antigens produced by St. Petersburg Research Institute for Vaccines and Sera of Russia’s Federal Medical and Biological Agency.
  • Partnership with Boehringer Ingelheim to localize a full-cycle manufacturing of the most advanced cardiovascular pharmaceutical products. The first commercial Metalyse® batches are produced.
  • Polyoxidonium® is a two-time winner of the Russian Pharma Awards (2016 and 2017). Polyoxidonium® tablets label is extended to include children aged 3+ years. A Post-Authorization Safety Study (PASS) for Polyoxidonium® is successfully completed in Europe (Slovakia).
  • Petrovax Pharm is announced the winner of the All-Russia Contest «Russian Business Leaders: Performance and Commitment’2017» in the category «For the Dynamic Development of Business».
  • Grippol® Quadrivalent registration dossier is submitted for review and approval.